# Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/niraparib-maintenance-therapy-in-patients-with-recurrent-ovarian-cancer-after-a/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Josep M. del Campo,Ursula A. Matulonis,Susanne Malander,Diane Provencher,Sven Mahner,Philippe Follana,Justin S. Waters,Jonathan S. Berek,Kathrine Woie,Amit M. Oza,Ulrich Canzler,Marta Gil-Martín,Anne Lesoin,Bradley J. Monk,Bente Lund,Lucy Gilbert,Robert M. Wenham,Benedict B. Benigno,Sujata Arora,Sebastien Hazard,Mansoor Raza Mirza |
| Citations | 194 |
| DOI | 10.1200/jco.18.02238 |
| Fields | Medicine |
| Open Access | true |
| OA Status | hybrid |
| OA URL | https://doi.org/10.1200/jco.18.02238 |
| OpenAlex ID | https://openalex.org/W2948947061 |
| PMID | 31173551 |
| Type | article |
| Year | 2019 |

## Paper authors

- [Bradley J. Monk](https://scholariq.org/researchers/bradley-j-monk/)
- [Sven Mahner](https://scholariq.org/researchers/sven-mahner/)
- [Amit M. Oza](https://scholariq.org/researchers/amit-m-oza/)
- [Mansoor Raza Mirza](https://scholariq.org/researchers/mansoor-raza-mirza/)

## Paper journal

- [Journal of Clinical Oncology](https://scholariq.org/journals/journal-of-clinical-oncology/)

## Paper primary topic

- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)

## Paper topics

- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)
- [Ovarian cancer diagnosis and treatment](https://scholariq.org/topics/ovarian-cancer-diagnosis-and-treatment/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.